Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac

This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its extraordinary meeting on 29 April 2021. Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Working Group website. The guidance is based on the evidence in the background document on the Sinovac-CoronaVac (COVID-19) vaccine and the annexes which include the GRADE and Evidence to Recommendation tables. Both these documents are available on the SAGE COVID-19 webpage: https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials. These interim recommendations refer to the inactivated vaccine against COVID-19 developed by Sinovac. The trade name of the vaccine is CoronaVac. In the subsequent text the vaccine will be referred to as Sinovac-CoronaVa

Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19

This background document on the Sinovac-CoronaVac vaccine was prepared by the Working Group on COVID-19 Vaccines of the Strategic Advisory Group of Experts (SAGE) on Immunization to inform SAGE deliberations. It contains the evidence summary which was considered by SAGE and served as the foundation for the WHO Interim recommendations referenced below. This background document was developed to inform the initial recommendation-making process. It is not updated on a regular basi